卖什么
Patient Intelligence Platform for Genetic Disease
商业模式拆解
买家：谁掌握预算？
Biotech and pharma (small biotech to top-20) paying for patient finding; patients get free or insurance-billed testing.
触发点：什么让他们现在购买？
Rare-disease patients are impossible to find for trials and commercialization; patients face a diagnostic odyssey.
工作流：什么输入变成什么输出？
Patients check eligibility, get free sponsored testing or insurance-billed testing with a genetic counselor; AI/ML/LLMs identify candidates for drug developers within compliant programs.
经济账：省了什么，怎么收费？
Two-sided: pharma/lab/advocacy partners fund free testing programs and patient discovery; insurance billing for other patients; 200,000+ patients, 50+ advocacy partners.
渠道：怎么接触到客户？
Patient advocacy group partnerships, partner sales ('Talk with our team'), online eligibility check.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2019 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.